All News
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
Day 2 Report from ACR21
This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.
Read Article
#ACR21 #Abstr1541 Any tools to help differentiate MAS vs #COVID inflammatory response? Preliminary criteria showed Sensitivity: 79.6%; Specificity: 81.3% within 6 days admission. No Triglyceride/Fibrinogen compared to 2016 ACR-EULAR & 2004 HLH @RheumNow https://t.co/c7pHaVCr5S https://t.co/6irF64qizI
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Will a FDA black box warning change your JAKi practice?
In May 2019, the EMA put out a warning about VTE with tofacitinib.
In this French cohort, did it change the kind of pts they initiated on JAKi?
no, not it did not😊
A window into the US future?
#ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
David Liew drdavidliew ( View Tweet)
Echos in PsA, RA:
🔹Diastolic dysfxn: 52% of PsA and RA (!), controls 5%
🔹Mitral regurge PsA 84%, Ra 53%, controls 10%
🔹Mild pulmonary valve regurge higher in PsA
(Diastolic dysfxn has been seen in prior RA studies)
https://t.co/QCKR5itfYj
#ACR21 Abst1308 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
Diabetes puts you at risk of cardiovascular disease, right?
What about RA?
Look at this graph and compare the pair.
"already it was impossible to say which was which” - George Orwell, Animal Farm
#ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn
David Liew drdavidliew ( View Tweet)
🔥Continued, More Clinically Meaningful data in #SSc #ILD from #Nintedanib in >52 wk SENSCIS & SENSCIS-ON(open-label ext)#ACR21 Dr Distler
✨MMF likely to stay 1st line, then Nintedanib
❓Is it time for MMF + Antifibrotic upfront??
Await SLS-III;Data so far seems supportive https://t.co/JWXMlsJgmc
Ashima Makol MD AshimaMakol ( View Tweet)
Among 6 CV risk algorithms, the best to predict the carotid plaque (CP) in PsA is the ACC/AHA risk score showed an AUC 0.681 (0.551-0.812), p=0.008, a cut-off point ≥4.8, sensitivity of 63.6%, and specificity of 64.4%
⭐️Prevalence CP 42.3%
Abst #1315 #ACR21 @RheumNow https://t.co/hRvyjetYq3
swethaann23 swethaann23 ( View Tweet)
Pulmonary Arterial Hypertension in #AOSD
Rare but severe complication - life threatening
French study of 13 pts - network dataset. ALL FEMALES!
Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED
@RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP
Bella Mehta bella_mehta ( View Tweet)
Knowledge Bowl at #ACR21
⭐️The first lung fibrosis described in Sjogren's with lung biopsy showing benign polyclonal lymphocytes and plasma cells with a risk for malignant transformation.
➡️Lymphocytic Interstitial Pneumonia
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#volcosporin good ~lupus nephritis added to #MMF but underbelly - side effects like but ?less than #cyclosporin. #FDA update - ⬆️hypertension and nephrotoxicity, infection #ACR21 @RheumNow https://t.co/w5nLLSTlrB
Janet Pope Janetbirdope ( View Tweet)
Almost like real-life, I've "run across the conference centre" to catch the end of the #InterstitialLungDisease session- some excellent insights from Dr Melissa Griffith on a complex topic, will definitely be reviewing the full talk later.
#ACR21 @RheumNow https://t.co/LdhXI8LLqY
Mrinalini Dey DrMiniDey ( View Tweet)
#ILD in #rheumatic diseases. When to use #glucocorticoids and immune suppressive sand anti fibrotic. V clear but harder in real world! @RheumNow #ACR21 #ACRBest https://t.co/R4V5ZggRsu
Janet Pope Janetbirdope ( View Tweet)
Steroids can cause co-morbidities which increase CV risk, but can PNL directly increase CV event (MACE) risk in RA?
30d PNL➡️15% increase in MACE in next 30d
(independent of underlying CV risk, RA dx activity)
PNL actively confers risk!
@BethIWallace #ACR21 ABST1428 @RheumNow https://t.co/cuL69n7cx3
David Liew drdavidliew ( View Tweet)
Plenary Abs#1428 #ACR21
👉🏼Long-term #steroid use is common in RA incl in pts with high risk of #MACE
👉🏼30days of steroids ➡️ 15% increased odds of MACE
@RheumNow
https://t.co/fCM3m04ruS https://t.co/FWGmAatYu5
Mrinalini Dey DrMiniDey ( View Tweet)
26K Veterans data with RA #ACR21 plenary abst#1428
30 days on glucocorticoids - ⬆️15% odds of Major Adverse Cardiovascular events @RheumNow @BethIWallace https://t.co/BOram4o2rp
Bella Mehta bella_mehta ( View Tweet)
Plenary Abs#1427 #ACR21
👉🏼#Statins assoc w/ reduced #CVD & all-cause mortality, outweighing
modest #T2DM risk increase in RA pts
👉🏼Reduction in all-cause mortality greater in RA than gen population
👉🏼Incr in T2DM risk is NOT greater in RA compared to gen population
@RheumNow https://t.co/WcF11B0C2s
Mrinalini Dey DrMiniDey ( View Tweet)
Statins in RA - plenary at #ACR21 UK Clinical
Practice Research Datalink 1989-2018 @RheumNow
Reduction in CVD risk, All cause mortality
INCREASE in Type 2 DM risk🧐 - need to make sure we look into it for RA patients!
Great work @UNMC_Rheum by Gulsen Ozen! https://t.co/YmTO0xcdjj
Bella Mehta bella_mehta ( View Tweet)
